Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

Immutep Limited (ASX: IMM; NASDAQ: IMMP), an immunotherapy company based in Sydney, has announced that data from its EFTISARC-NEO Phase II trial has been accepted for oral presentation at the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting, scheduled for November 12-15, 2025, in Boca Raton, Florida. This trial represents the first evaluation of eftilagimod alpha (efti) in a neoadjuvant setting—prior to surgery—combined with radiotherapy and Merck's KEYTRUDA® (pembrolizumab) for patients with soft tissue sarcoma (STS), a group of rare and challenging cancers characterized by high unmet medical need.

The oral presentation, titled "Primary endpoint and translational correlates from EFTISARC-NEO: phase II trial of neoadjuvant eftilagimod alpha (efti), pembrolizumab, and radiotherapy in patients with resectable soft tissue sarcoma," will be delivered by Dr. Pawel Sobczuk from the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Poland. It is set for November 13, 2025, during the session focused on Immunotherapy & Cell Therapy in Sarcoma.

In the United States alone, approximately 13,520 new cases of STS are anticipated in 2025, leading to around 5,420 deaths, highlighting the critical need for effective treatments. The EFTISARC-NEO trial is funded by a Polish government grant, underscoring the collaborative effort in the fight against this orphan disease.

Immutep continues to pioneer in immune response modulation through its exploration of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), aiming to bring innovative treatment options to patients while maximizing shareholder value. Presentation materials will be accessible on Immutep’s website following the event. For more details, interested parties can visit clinicaltrials.gov (NCT06128863).

Immutep Limited (ASX: IMM; NASDAQ: IMMP) has made a significant step in the field of oncology with the announcement that data from its EFTISARC-NEO Phase II trial has been accepted for oral presentation at the CTOS 2025 Annual Meeting. This trial evaluates eftilagimod alpha, an innovative immunotherapy, combined with pembrolizumab (KEYTRUDA®) and radiotherapy for patients with resectable soft tissue sarcoma (STS).

Soft tissue sarcoma represents a considerable unmet medical need, given its high mortality rate and the limited treatment options currently available. The latest statistical data indicates a forecast of approximately 13,520 new cases in the U.S. in 2025. The acceptance of this trial for presentation is a testament to the potential of Immutep’s therapeutic approach in addressing an orphan disease with dire prognostic implications.

Investors should closely monitor developments leading up to the presentation on November 13, 2025. Positive results from EFTISARC-NEO could enhance investor sentiment and lead to increased stock demand, particularly given the backing of the Polish government through the Polish Medical Research Agency. The presentation will detail the primary endpoints and correlates, providing crucial insights into the efficacy of the combination therapy.

Looking ahead, continued advancements in the trial and prospective regulatory approvals could significantly boost Immutep’s market position. Therefore, it may be prudent for investors to consider accumulating shares leading up to the presentation, as favorable outcomes could catalyze upward momentum in the stock price. However, potential investors should also weigh the inherent risks associated with clinical trials and regulatory processes in the biotech sector. As always, thorough due diligence and consideration of market dynamics are advisable prior to making investment decisions.